Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
Trump Administration Approves Nvidia H200 AI Chip Sales to China Under New Export Rules 
U.S. Government Invests $1 Billion in L3Harris Rocket Motor Business to Secure Missile Supply Chain 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
HSBC Expands UAE Presence With New Asset Management Business and Onshore Funds 
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s 
Boeing 737 MAX 10 Advances in FAA Testing as Certification Delays Continue 
AFT Leaves X Over AI-Generated Images of Minors 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
NYC Nurses Strike Shuts Down 10 Private Hospitals as 15,000 Demand Safer Staffing and Benefits 
Trump Weighs Blocking Exxon Investment as Venezuela Deemed “Uninvestable” 
NEW YORK, March 29, 2017 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, announced today data presentations related to Anavex’s Alzheimer’s disease pipeline as well as Christopher U. Missling, PhD, President and Chief Executive Officer, participating on a panel at the 13th International Conference on Alzheimer's and Parkinson's Diseases. The conference takes place from March 29 to April 2, 2017, in Vienna, Austria.
Panel Title: AD/PD™ 2017 FORUM ON TRANSLATIONAL RESEARCH IN DRUG DISCOVERY FOR AD: A PLETHORA OF TARGETS: WHICH IS THE BEST, IS THERE "A BEST ONE"?
Date/Time: Thursday, March 30; 2:45 p.m. - 4:45 p.m. CET
Location: HALL A
Oral Presentation Title: TARGETING M1 MUSCARINIC AND SIGMA-1 RECEPTORS IN ALZHEIMER'S DISEASE: REVERSAL OF PATHOLOGICAL HALLMARKS AND ASSOCIATED COGNITIVE DYSFUNCTION IN MCGILL-R-THY1-APP RATS (Data related to ANAVEX 3-71)
Date/Time: Thursday, March 30; 7.00 p.m. - 7.15 p.m. CET
Location: HALL A
Poster Presentation Title: THE DUAL REGULATION OF OXIDATIVE STRESS BY SIGMA1 RECEPTORS IN PHYSIOLOGICAL OR PATHOLOGICAL CONDITIONS (Data related to ANAVEX 2-73, ANAVEX 3-71, ANAVEX 1-41)
Date/Time: Saturday, April 1; 8.00 a.m. - 6.00 p.m. CET
Location: Poster Number 007
Data will be available on the Anavex website www.anavex.com concurrently with the respective sessions.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, recently successfully completed a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors and successfully completed Phase 1. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com. You can also connect with the company on Twitter, Facebook and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: [email protected] Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 [email protected] Media: Dennis Dobson, Jr. Dobson Media Group 203-258-0159 [email protected]
